156603-10-0 Usage
Derivative of benzene
Yes
Explanation
Different sources of media describe the Explanation of 156603-10-0 differently. You can refer to the following data:
1. The compound is derived from benzene, which is a hydrocarbon with a six-carbon ring structure and delocalized pi electrons.
2. The presence of a bromine atom (Br) in the compound contributes to its reactivity and properties.
3. A methoxy group (-OCH3) is a functional group consisting of an oxygen atom bonded to a methyl group. It is present in this compound, affecting its reactivity and properties.
4. A dioxolane ring is a four-membered ring containing two oxygen atoms. It is part of the compound's structure, contributing to its unique properties.
5. The compound is used as a reagent in organic synthesis to create other chemical compounds, due to its reactive functional groups.
6. Its unique structure and potential for producing biologically active compounds make it valuable in the development of new pharmaceuticals.
7. Bromine compounds can be hazardous, and appropriate safety measures should be taken when handling this compound.
8. To minimize the risk of exposure to hazardous bromine compounds, it is essential to work in a well-ventilated area and follow proper safety protocols.
Contains a bromine atom
Yes
Contains a methoxy group
Yes
Contains a dioxolane ring
Yes
Used in organic synthesis
Yes
Used in pharmaceutical research and development
Yes
Hazardous nature
Yes
Handling precautions
Well-ventilated area, appropriate safety measures
Check Digit Verification of cas no
The CAS Registry Mumber 156603-10-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,6,0 and 3 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 156603-10:
(8*1)+(7*5)+(6*6)+(5*6)+(4*0)+(3*3)+(2*1)+(1*0)=120
120 % 10 = 0
So 156603-10-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H11BrO3/c1-12-9-3-2-7(11)6-8(9)10-13-4-5-14-10/h2-3,6,10H,4-5H2,1H3
156603-10-0Relevant articles and documents
ALPHAvBETA1 INTEGRIN ANTAGONISTS
-
Paragraph 0277; 0314, (2020/01/31)
The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ1 and/or α5β1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ3, ανβ5, ανβ6, ανβ8, and/or αIIbβ3.
Substituted Pyrrolidines and Methods of Use
-
Paragraph 2042, (2018/04/20)
The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Glycoside Derivatives and Uses Thereof
-
Page/Page column 54, (2011/08/02)
This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
